Shock, Hemorrhagic: Clinical Trials

3 trials for Shock, Hemorrhagic, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 terminated. 3 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 13Completed 2, Terminated 1
Phase 21Completed 1

Follow Shock, Hemorrhagic: new trials by email Literature Review of Shock, Hemorrhagic trials Research Report on Shock, Hemorrhagic

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Safety and Tolerability of Valproic Acid in Trauma Patients(Part 2)
Valproic Acid, Isotonic saline solution - Shock,Hemorrhagic, Trauma
Phase 1TerminatedDr. Hasan Alam12016-11-012017-11-06
A Study to Evaluate the Safety and Tolerability of Valproic Acid in Healthy Volunteers (Part 1)
Valproic Acid, Isotonic saline solution - Shock,Hemorrhagic
Phase 1CompletedDr. Hasan Alam592013-09-012016-12-19
The Trauma- Formula-Driven Versus Lab-Guided Study (TRFL Study)
Massive transfusion protocol, Standard of care - Hemorrhagic Shock, Trauma Coagulopathy
Phase 1 / Phase 2CompletedSunnybrook Health Sciences Centre702009-07-012011-12-02

Narrower conditions

Wounds and Injuries (2)  ·  Hemostatic Disorders (1)

Broader conditions

Hemorrhage (3)  ·  Pathologic Processes (3)  ·  Pathological Conditions, Signs and Symptoms (3)  ·  Shock (3)  ·  Cardiovascular Diseases (1)  ·  Hematologic Diseases (1)  ·  Hemic and Lymphatic Diseases (1)  ·  Hemorrhagic Disorders (1)  ·  Vascular Diseases (1)

Interventions

Valproic Acid (2)  ·  Standard of Care (1)

Sponsors

Dr. Hasan Alam (2)  ·  Sunnybrook Health Sciences Centre (1)

Countries

United States (2)  ·  Canada (1)

Top investigators

Hasan Alam, MD (2)  ·  Gordon D Rubenfeld, MD, MSc (1)  ·  Homer C Tien, MD, MSc (1)  ·  Sandro B Rizoli, MD PhD (1)

Results publications

PMID 22071998, PMID 23857856, PMID 28497259